Abstract:
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R 1 , R 2 , R 3 , L, L 1 , L 2 , L 3 , M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.
Abstract:
Disclosed is a marking composition comprising a marker and a hydrogel. Disclosed is a process of forming a marking composition comprising mixing a marker and a hydrogel. Disclosed is an article comprising a marker, a hydrogel, and an implement. Disclosed is a kit comprising a marker, a hydrogel, and an implement, wherein the marker and hydrogel are combined. Disclosed is a method for marking a portion of the brain in a mammal comprising: (a) removing a portion of a mammal's skull to expose a portion of the brain matter; and (b) contacting the exposed portion of the brain with a marking composition. Disclosed is a method for recording electrical activity in a brain, comprising: ( a) removing a portion of the skull, thereby exposing a portion of a brain; (b) inserting an electrode into the brain; and (c) recording electrical activity via the electrode, wherein the electrode is at least partially coated with a marking composition.
Abstract:
Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
Abstract:
Described herein are compounds and methods useful in the detection of, e.g., Zn2+, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn2+. The peptides may be further functionalized with a detectable moiety. The peptides may also comprise amino acid sequences known to localize extracellularly or in specific areas within a cell.
Abstract:
본 명세서에는 세포 투과성 펩티드 및 유효성분의 컨쥬게이트(conjugate), 및 그 용도가 개시된다. 특히, 세포 투과성 펩티드로서 서열 번호 2 내지 서열번호 178 중 어느 한 서열을 갖는 펩티드, 서열 번호 2 내지 서열번호 178 중 어느 한 서열의 단편인 펩티드 또는 상기 펩티드 서열과 80% 이상의 서열 상동성을 갖는 펩티드를 포함하는 컨쥬게이트 및 그것을 포함하는 조성물이 개시된다.
Abstract translation:公开了细胞穿透肽,作为活性成分的缀合物及其用途。 更具体地,公开了具有SEQ ID NO:1中的一个序列的细胞穿透肽。 2至SEQ ID NO。 178是包含作为SEQ ID NO:1的一个序列的片段的肽的缀合物。 2至SEQ ID NO。 178或具有与肽序列至少80%同源的序列的肽,以及包含该缀合物的组合物。
Abstract:
Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes.